Click to view the full report TOC, figure and tables：
Email us with your all Requirements,
Request A Sample and Brochure or Request For Custom Research (price, discount, regional reports, and chapters only, analyst talk and etc.)
Please Email US:
Benefits of Purchasing QYResearch Research Report
- Analyst SupportGet you queries resolved from our expert analysts before and after purchasing the report
- Customer’s SatisfactionOur expert team will assist with all your research needs and customize the report
- Inimitable ExpertiseAnalysts will provide deep insights about the reports
- Assured QualityWe focus on the quality and accuracy of the report
The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
Monoclonal Antibodies having the potential to offer less toxic and efficient therapeutic alternatives to the patients have been emerging in the recent years. Monoclonal Antibodies are used to treat a wide array of diseases related to autoimmune, inflammatory and especially cancer. Monoclonal Antibodies (mAbs) are mono-specific antibodies bodies comprising of identical immune cells that are clones of a single parent cells and are directed to a specific cellular targets. Thus Monoclonal Antibodies are highly customizable due to its specific nature and can play a crucial role in eliminating the cancerous cell while sparing the normal cells during the cancer treatment. The monoclonal antibodies are proved to be more effective than chemotherapies and drugs for cancer treatment.
The global Cancer Monoclonal Antibodies market is valued at xx million US$ in 2017 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2018-2025.
The major players covered in this report
F. Hoffmann-La Roche
Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
We can also provide the customized separate regional or country-level reports, for the following regions:
Rest of Asia-Pacific
Rest of Europe
Central & South America
Rest of South America
Middle East & Africa
Rest of Middle East & Africa
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
Hodgkins and Non-Hodgkins lymphoma
Request Sample Copy of the Report @
About US:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.
QY Research, INC.
17890 Castleton, Suite 218,
City of industry, CA – 91748
USA: +1 6262 952 442
China: +86 1082 945 717
Japan: +81 9038 009 273
India: +91 9766 478 224
Emails – email@example.com
Web – www.qyresearch.com
Expert News: https://www.qyresearch.com/expert/list